Mobia Medical Inc

Mobia Medical shares jumped about 7.2% in premarket trading after the American Heart Association/American Stroke Association included paired vagus nerve stimulation (VNS) in its 2026 stroke rehabilitation guideline. The guideline recommends VNS combined with high‑dose, task‑specific training to improve upper‑limb function in suitable patients. Mobia’s Vivistim Paired VNS System is the only FDA‑approved system for this approach, and the guidelines emphasize ongoing functional assessments and treatment continuity for at least one year. » More on de.investing.com

Mobia Medical reported Q2 2026 revenue of $13.5m (up 102% year‑over‑year) and a net loss of $21.0m ($1.10 per share). Gross margin improved to 83.2%, active sales territories rose to 35.5, and units sold were about 367. The company raised its 2026 revenue guidance to $54–56m and held $177.1m in cash and cash equivalents at quarter end. SG&A and R&D expenses increased significantly; the stock closed down 1.18% at $12.58 and showed no after-hours movement. » More on de.investing.com